UK markets close in 2 hours 5 minutes

Novozymes A/S (NZYM-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
398.10-2.60 (-0.65%)
As of 03:23PM CEST. Market open.
Full screen
Previous close400.70
Open400.70
Bid398.20 x 0
Ask398.30 x 0
Day's range397.10 - 401.30
52-week range362.60 - 545.80
Volume70,571
Avg. volume276,624
Market cap109.996B
Beta (5Y monthly)0.35
PE ratio (TTM)35.80
EPS (TTM)11.12
Earnings date26 Oct 2022
Forward dividend & yield5.50 (1.44%)
Ex-dividend date17 Mar 2022
1y target est423.42
  • Globe Newswire

    Novozymes delivers strong half year results and narrows full-year outlook upwards

    Novozymes delivered solid earnings and double-digit organic sales growth in both the first half and in the second quarter. Despite the volatile market environment, the company narrows its full-year organic sales outlook upwards from 4-8% to now 6-8% and raises EBIT-margin expectations from 25-26% to now 26-27%. COPENHAGEN, Denmark – August 11, 2022. Novozymes delivers 10% organic sales growth and an EBIT-margin of 26% in the first half of the year, with 18% organic sales growth in DKK. Good mome

  • Globe Newswire

    Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost

    Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. To recover these headwinds, substantial price increases will be implemented. COPENHAGEN, Denmark – 15 July 2022. Novozymes has been able to partially shield its customers from a large part of the global challenges, securing business continuity and high price stability relative to other suppliers. However, Novozymes will further substantially increase prices at a level at least in line with the current

  • Zacks

    AXTA vs. NVZMY: Which Stock Is the Better Value Option?

    AXTA vs. NVZMY: Which Stock Is the Better Value Option?